Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$644K Buy
5,013
+123
+3% +$14.4K 0.14% 120
2026
Q1
$588K Buy
4,890
+319
+7% +$36.8K 0.14% 124
2025
Q4
$481K Sell
4,571
-69
-1% -$6.48K 0.12% 135
2025
Q3
$418K Buy
4,640
+2
+0% +$165 0.11% 152
2025
Q2
$367K Sell
4,638
-15
-0.3% -$1.19K 0.1% 163
2025
Q1
$418K Sell
4,653
-684
-13% -$63.9K 0.13% 142
2024
Q4
$531K Sell
5,337
-233
-4% -$24K 0.16% 115
2024
Q3
$633K Buy
5,570
+172
+3% +$20.4K 0.19% 101
2024
Q2
$690K Sell
5,398
-169
-3% -$21.8K 0.23% 90
2024
Q1
$735K Sell
5,567
-454
-8% -$56K 0.26% 81
2023
Q4
$656K Buy
6,021
+179
+3% +$18.6K 0.27% 82
2023
Q3
$601K Sell
5,842
-13
-0.2% -$1.4K 0.27% 87
2023
Q2
$676K Buy
5,855
+3
+0.1% +$341 0.29% 74
2023
Q1
$623K Buy
5,852
+354
+6% +$38.2K 0.29% 80
2022
Q4
$610K Buy
+5,498
New +$562K 0.32% 76

Other funds holding MRK

Westmount Partners's MRK Position: Q2 2026 in Review

Westmount Partners increased its Merck (MRK) stake by 2.5% in Q2 2026, buying an estimated $14.4K and bringing the position to 5,013 shares worth $644K. The position accounts for 0.14% of the portfolio, ranked #120.

Westmount Partners first reported a position in MRK in Q4 2022 and has held it in 15 quarters since. The position peaked at $735K in Q1 2024. 1,867 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Westmount Partners held 5,013 shares of Merck worth $644K as of Q2 2026.
  • Westmount Partners bought 123 Merck shares in Q2 2026, an estimated $14.4K.
  • Merck made up 0.14% of Westmount Partners's portfolio in Q2 2026, its #120 holding.
  • Westmount Partners first reported a position in Merck in Q4 2022 and has held it in 15 quarters since.
  • Westmount Partners's Merck position peaked at $735K in Q1 2024.
  • 1,867 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Westmount Partners's 13F filing for Q2 2026, filed 7 Jul 2026.